Study List:
`
`Study 1:
` Title: A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder
`Overactivity Caused By A Neurological Condition
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Urinary Bladder, Neurogenic
` Interventions: Drug: Fesoterodine PR 4 mg|Drug: Fesoterodine PR 8 mg|Drug: Fesoterodine PR 8 mg|Drug:
`Oxybutynin|Drug: Fesoterodine PR|Drug: Fesoterodine BIC 2 mg|Drug: Fesoterodine BIC 4 mg
` Sponsor/Collaborators: Pfizer
` Start Date: July 2012
` Completion Date: April 2019
` URL: https://ClinicalTrials.gov/show/NCT01557244
`
`Study 2:
` Title: Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients
`With Overactive Bladder
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: Fesoterodine|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: May 2010
` Completion Date: January 2012
` URL: https://ClinicalTrials.gov/show/NCT01054222
`
`Study 3:
` Title: Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic
`Detrusor Overactivity.
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Urinary Bladder, Neurogenic
` Interventions: Drug: Fesoterodine PR 4 mg|Drug: Fesoterodine PR 8 mg|Drug: Fesoterodine BIC 2 mg|Drug:
`Fesoterodine BIC 4 mg
` Sponsor/Collaborators: Pfizer
` Start Date: June 2015
` Completion Date: June 2019
` URL: https://ClinicalTrials.gov/show/NCT02501928
`
`Study 4:
` Title: This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In
`Patients With Symptoms Of Overactive Bladder
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine|Behavioral: Your Way
` Sponsor/Collaborators: Pfizer
` Start Date: July 2009
` Completion Date: November 2010
` URL: https://ClinicalTrials.gov/show/NCT00943735
`
`Study 5:
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 1
`
`

`
` Title: This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
` Interventions: Drug: fesoterodine|Drug: fesoterodine|Drug: fesoterodine|Drug: fesoterodine|Drug:
`fesoterodine|Drug: fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: December 2010
` Completion Date: March 2011
` URL: https://ClinicalTrials.gov/show/NCT01286454
`
`Study 6:
` Title: A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly
`Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: Placebo|Drug: Fesoterodine fumarate
` Sponsor/Collaborators: Pfizer
` Start Date: June 2008
` Completion Date: September 2010
` URL: https://ClinicalTrials.gov/show/NCT00798434
`
`Study 7:
` Title: A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy
`Subjects
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Treatment of Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: May 2009
` Completion Date: June 2009
` URL: https://ClinicalTrials.gov/show/NCT00902187
`
`Study 8:
` Title: The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
` Interventions: Drug: Fesoterodine|Drug: fesoterodine plus fluconazole
` Sponsor/Collaborators: Pfizer
` Start Date: May 2009
` Completion Date: July 2009
` URL: https://ClinicalTrials.gov/show/NCT00911235
`
`Study 9:
` Title: Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Over Active Bladder
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: February 2011
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 2
`
`

`
` Completion Date: October 2013
` URL: https://ClinicalTrials.gov/show/NCT01260311
`
`Study 10:
` Title: A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the
`Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: Fesoterodine 8 mg|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: May 2011
` Completion Date: May 2012
` URL: https://ClinicalTrials.gov/show/NCT01302054
`
`Study 11:
` Title: A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy
`Subjects
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Treatment of Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: June 2009
` Completion Date: August 2009
` URL: https://ClinicalTrials.gov/show/NCT00902681
`
`Study 12:
` Title: UK Study Assessing Flexible Dose Fesoterodine in Adults
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: February 2009
` Completion Date: January 2010
` URL: https://ClinicalTrials.gov/show/NCT00806494
`
`Study 13:
` Title: A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The
`Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: fesoterodine fumarate|Drug: fesoterodine fumarate|Drug: fesoterodine fumarate|Drug:
`fesoterodine fumarate|Drug: fesoterodine fumarate
` Sponsor/Collaborators: Pfizer
` Start Date: May 2012
` Completion Date: July 2012
` URL: https://ClinicalTrials.gov/show/NCT01566760
`
`Study 14:
` Title: A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
` Recruitment: Completed
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 3
`
`

`
` Study Results: Has Results
` Conditions: Healthy
` Interventions: Drug: 4mg fesoterodine|Drug: 8mg fesoterodine|Drug: alprazolam 1mg|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: July 2010
` Completion Date: September 2010
` URL: https://ClinicalTrials.gov/show/NCT01161472
`
`Study 15:
` Title: Drug Use Investigation for Toviaz
` Recruitment: Active, not recruiting
` Study Results: No Results Available
` Conditions: Overactive Bladder (OAB)
` Interventions: Drug: Fesoterodine (Toviaz)
` Sponsor/Collaborators: Pfizer
` Start Date: October 2013
` Completion Date: May 2016
` URL: https://ClinicalTrials.gov/show/NCT01936870
`
`Study 16:
` Title: Non-Interventional Study To Investigate Whether Information Provided To Patients Influences
`Their Satisfaction With Toviaz Therapy
` Recruitment: Terminated
` Study Results: Has Results
` Conditions: Urinary Bladder, Overactive
` Interventions: Other: Toviaz(fesoterodine) plus educational materials|Other: Toviaz(fesoterodine) without
`educational materials
` Sponsor/Collaborators: Pfizer
` Start Date: December 2010
` Completion Date: May 2012
` URL: https://ClinicalTrials.gov/show/NCT01091519
`
`Study 17:
` Title: Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder|Neurogenic Detrusor Overactivity
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: March 2009
` Completion Date: December 2010
` URL: https://ClinicalTrials.gov/show/NCT00857896
`
`Study 18:
` Title: Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet
`Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-
`capsule Formulations in Healthy Adult Volunteers
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Healthy
` Interventions: Drug: Fesoterodine ER (fasted)|Drug: Fesoterodine SR3 (fasted)|Drug: Fesoterodine SR3
`(fed)|Drug: Fesoterodine ER (fed)|Drug: Fesoterodine SR3 (sprinkle)|Drug: Fesoterodine ER (fasted)|Drug:
`Fesoterodine SR4 (fasted)|Drug: Fesoterodine SR4 (fed)|Drug: Fesoterodine ER (fed)|Drug: Fesoterodine SR4
`(sprinkle)
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 4
`
`

`
` Sponsor/Collaborators: Pfizer
` Start Date: July 2014
` Completion Date: December 2014
` URL: https://ClinicalTrials.gov/show/NCT02160158
`
`Study 19:
` Title: Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On
`Gastrointestinal Transit
` Recruitment: Terminated
` Study Results: Has Results
` Conditions: Healthy
` Interventions: Drug: fesoterodine fumarate|Drug: placebo|Drug: solifenacin
` Sponsor/Collaborators: Pfizer
` Start Date: April 2009
` Completion Date: December 2009
` URL: https://ClinicalTrials.gov/show/NCT00832650
`
`Study 20:
` Title: Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary
`Incontinence Patients
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Stress Urinary Incontinence
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: January 2009
` Completion Date: July 2010
` URL: https://ClinicalTrials.gov/show/NCT01042236
`
`Study 21:
` Title: Fesoterodine "add-on" Male Overactive Bladder Study
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder Syndrome
` Interventions: Drug: Fesoterodine|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: November 2007
` Completion Date: February 2009
` URL: https://ClinicalTrials.gov/show/NCT00546637
`
`Study 22:
` Title: A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive
`Bladder
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: September 2009
` Completion Date: September 2011
` URL: https://ClinicalTrials.gov/show/NCT00928070
`
`Study 23:
` Title: A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 5
`
`

`
`Overactive Bladder Including Nocturnal Urinary Urgency
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: August 2009
` Completion Date: September 2011
` URL: https://ClinicalTrials.gov/show/NCT00911937
`
`Study 24:
` Title: A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of
`Fesoterodine
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine 8mg|Drug: Fesoterodine 4mg|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: May 2011
` Completion Date: November 2012
` URL: https://ClinicalTrials.gov/show/NCT01302067
`
`Study 25:
` Title: Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous
`Therapy
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder|Urinary Incontinence
` Interventions: Drug: fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: July 2008
` Completion Date: June 2009
` URL: https://ClinicalTrials.gov/show/NCT00691093
`
`Study 26:
` Title: Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In
`Comparison To Placebo For Overactive Bladder.
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: fesoterodine fumarate|Drug: Placebo|Drug: fesoterodine fumarate
` Sponsor/Collaborators: Pfizer
` Start Date: November 2007
` Completion Date: January 2009
` URL: https://ClinicalTrials.gov/show/NCT00561951
`
`Study 27:
` Title: A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In
`Overactive Bladder Patients
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: fesoterodine fumarate
` Sponsor/Collaborators: Pfizer
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 6
`
`

`
` Start Date: January 2007
` Completion Date: October 2007
` URL: https://ClinicalTrials.gov/show/NCT00425100
`
`Study 28:
` Title: The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy
`Subjects
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Urinary Bladder, Overactive
` Interventions: Drug: warfarin|Drug: Warfarin plus Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: July 2009
` Completion Date: August 2009
` URL: https://ClinicalTrials.gov/show/NCT00914667
`
`Study 29:
` Title: Fesoterodine Flexible Dose Study
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Placebo
` Sponsor/Collaborators: Pfizer
` Start Date: August 2007
` Completion Date: March 2008
` URL: https://ClinicalTrials.gov/show/NCT00536484
`
`Study 30:
` Title: Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive
`Bladder.
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: fesoterodine fumarate
` Sponsor/Collaborators: Pfizer
` Start Date: February 2008
` Completion Date: August 2009
` URL: https://ClinicalTrials.gov/show/NCT00658684
`
`Study 31:
` Title: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for
`Overactive Bladder (OAB)
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: fesoterodine fumarate|Drug: placebo|Drug: tolterodine tartrate
` Sponsor/Collaborators: Pfizer
` Start Date: April 2007
` Completion Date: July 2008
` URL: https://ClinicalTrials.gov/show/NCT00444925
`
`Study 32:
` Title: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine
`Extended Release(ER)in Patients With Overactive Bladder.
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 7
`
`

`
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: February 2008
` Completion Date: October 2009
` URL: https://ClinicalTrials.gov/show/NCT00611026
`
`Study 33:
` Title: Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Therapeutic Equivalency|Food
` Interventions: Drug: Fesoterodine|Drug: Fesoterodine|Drug: Fesoterodine|Drug: Fesoterodine|Drug:
`Fesoterodine|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: October 2008
` Completion Date: December 2008
` URL: https://ClinicalTrials.gov/show/NCT00807118
`
`Study 34:
` Title: Phase1, Single Dose, Crossover Study to Determine Bioequivalence
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Healthy
` Interventions: Drug: Fesoterodine|Drug: Fesoterodine
` Sponsor/Collaborators: Pfizer
` Start Date: January 2009
` Completion Date: February 2009
` URL: https://ClinicalTrials.gov/show/NCT00786240
`
`Study 35:
` Title: Toviaz Post Marketing Surveillance Study
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Overactive Bladder
` Interventions: Drug: Toviaz treatment
` Sponsor/Collaborators: Pfizer
` Start Date: November 2009
` Completion Date: August 2014
` URL: https://ClinicalTrials.gov/show/NCT00879398
`
`Study 36:
` Title: Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release
`Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension
`Phase
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder
` Interventions: Drug: SPM 907
` Sponsor/Collaborators: Pfizer
` Start Date: June 2003
` Completion Date: June 2007
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 8
`
`

`
` URL: https://ClinicalTrials.gov/show/NCT00220389
`
`Study 37:
` Title: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine
`(SP584) for the Treatment of Overactive Bladder Syndrome
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder Syndrome
` Interventions: Drug: SPM 907
` Sponsor/Collaborators: Pfizer
` Start Date: April 2004
` Completion Date: July 2007
` URL: https://ClinicalTrials.gov/show/NCT00220376
`
`Study 38:
` Title: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine
`(SP583) for the Treatment of Overactive Bladder Syndrome
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder Syndrome
` Interventions: Drug: SPM 907
` Sponsor/Collaborators: Pfizer
` Start Date: July 2004
` Completion Date: July 2007
` URL: https://ClinicalTrials.gov/show/NCT00220402
`
`Study 39:
` Title: Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in
`Subjects With Overactive Bladder Syndrome
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder
` Interventions: Drug: SPM 907
` Sponsor/Collaborators: Pfizer
` Start Date: October 2003
` Completion Date: February 2005
` URL: https://ClinicalTrials.gov/show/NCT00138723
`
`Study 40:
` Title: A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder Syndrome
` Interventions: Drug: SPM 907
` Sponsor/Collaborators: Pfizer
` Start Date: January 2004
` Completion Date: February 2005
` URL: https://ClinicalTrials.gov/show/NCT00220363
`
`Study 41:
` Title: Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Overactive Bladder
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 9
`
`

`
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: Stéphane Bolduc|Pfizer|Centre Hospitalier Universitaire de Québec, CHU de
`Québec
` Start Date: October 2015
` Completion Date: March 2017
` URL: https://ClinicalTrials.gov/show/NCT02614482
`
`Study 42:
` Title: A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
` Recruitment: Not yet recruiting
` Study Results: No Results Available
` Conditions: Overactive Bladder|Mild Cognitive Impairment
` Interventions: Drug: fesoterodine 4mg|Drug: Oxybutynin|Drug: placebo|Drug: fesoterodine 8mg
` Sponsor/Collaborators: University of Alberta|Pfizer
` Start Date: May 2016
` Completion Date: June 2018
` URL: https://ClinicalTrials.gov/show/NCT02240459
`
`Study 43:
` Title: Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
` Recruitment: Enrolling by invitation
` Study Results: No Results Available
` Conditions: Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Oxybutynin XL
` Sponsor/Collaborators: Stéphane Bolduc|Pfizer|Centre Hospitalier Universitaire de Québec, CHU de
`Québec
` Start Date: December 2014
` Completion Date: September 2016
` URL: https://ClinicalTrials.gov/show/NCT02327936
`
`Study 44:
` Title: An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign
`Prostatic Hyperplasia
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Bladder Outlet Obstruction
` Interventions: Drug: Toviaz (Fesoterodine)
` Sponsor/Collaborators: Weill Medical College of Cornell University|Pfizer
` Start Date: January 2010
` Completion Date: null
` URL: https://ClinicalTrials.gov/show/NCT00605319
`
`Study 45:
` Title: Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Autonomic Dysreflexia
` Interventions: Drug: Fesoterodine
` Sponsor/Collaborators: University of British Columbia|Pfizer|International Collaboration On Repair
`Discoveries (ICORD)|Vancouver Coastal Health
` Start Date: February 2016
` Completion Date: October 2016
` URL: https://ClinicalTrials.gov/show/NCT02676154
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 10
`
`

`
`Study 46:
` Title: Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
` Recruitment: Completed
` Study Results: Has Results
` Conditions: Urge Urinary Incontinence|Overactive Bladder
` Interventions: Drug: Fesoterodine|Drug: Matching Placebo
` Sponsor/Collaborators: University of California, San Francisco|Pfizer
` Start Date: January 2009
` Completion Date: May 2011
` URL: https://ClinicalTrials.gov/show/NCT00862745
`
`Study 47:
` Title: Premarin Versus Toviaz for Treatment of Overactive Bladder
` Recruitment: Recruiting
` Study Results: No Results Available
` Conditions: Overactive Bladder
` Interventions: Drug: Toviaz, Premarin Vaginal Cream
` Sponsor/Collaborators: Cleveland Clinic Florida|Pfizer
` Start Date: April 2012
` Completion Date: April 2013
` URL: https://ClinicalTrials.gov/show/NCT01613170
`
`Study 48:
` Title: Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder
` Recruitment: Completed
` Study Results: No Results Available
` Conditions: Overactive Bladder
` Interventions: Drug: Toviaz
` Sponsor/Collaborators: University of Pennsylvania|Pfizer
` Start Date: May 2011
` Completion Date: December 2013
` URL: https://ClinicalTrials.gov/show/NCT01925456
`
`file:///Y|/...linicalTrials.gov%20-%20Fesoterodine%20Clinical%20Studies%20Sponsored%20by%20Pfizer%20(accessed%2020160613).TXT[8/17/2016 4:33:45 PM]
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1070 - Page 11